Roche Drug Helps Elderly Be Cancer-Free for Longer

21 January 2010 (Last Updated January 21st, 2010 18:30)

Elderly patients taking Roche's drug Xeloda for colorectal cancer live disease-free for longer, the company said. Patients older than 65 and 70 taking Xeloda (capecitabine) with oxaliplatin (Xelox) immediately after surgery live disease-free for longer compared with those treated with

Elderly patients taking Roche's drug Xeloda for colorectal cancer live disease-free for longer, the company said.

Patients older than 65 and 70 taking Xeloda (capecitabine) with oxaliplatin (Xelox) immediately after surgery live disease-free for longer compared with those treated with commonly used chemotherapy regimen 5-fluorouracil/leucovorin, a study has shown.

The drug is already approved for the treatment of early-stage colon cancer as a monotherapy and in July 2009 Roche said a late-stage trial showed it increased the time patients lived when taken with oxaliplatin.